{"id":35990,"date":"2025-10-20T09:13:30","date_gmt":"2025-10-20T07:13:30","guid":{"rendered":"https:\/\/ggba.swiss\/essilorluxottica-acquires-bern-based-retinai-to-accelerate-ai-powered-eye-health-innovation\/"},"modified":"2025-10-20T11:23:40","modified_gmt":"2025-10-20T09:23:40","slug":"essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/","title":{"rendered":"EssilorLuxottica acquiert RetinAI pour acc\u00e9l\u00e9rer l\u2019innovation en sant\u00e9 visuelle pilot\u00e9e par l\u2019IA"},"content":{"rendered":"\n

Le leader mondial des soins de la vue EssilorLuxottica<\/a> a acquis Ikerian AG, l\u2019entreprise bernoise de technologies de la sant\u00e9 op\u00e9rant sous la marque RetinAI<\/a>. Cette acquisition constitue une \u00e9tape cl\u00e9 dans la strat\u00e9gie medtech du groupe, \u00e9largissant son portefeuille avec des outils avanc\u00e9s d\u2019apprentissage automatique et d\u2019analyse de donn\u00e9es destin\u00e9s \u00e0 am\u00e9liorer les processus cliniques, de recherche et pharmaceutiques.<\/p>\n\n\n\n

Fond\u00e9e en 2017, RetinAI d\u00e9veloppe des plateformes logicielles aliment\u00e9es par l\u2019intelligence artificielle pour collecter, traiter et analyser de vastes ensembles d\u2019images r\u00e9tiniennes et de biomarqueurs. Sa plateforme RetinAI Discovery\u00ae, certifi\u00e9e FDA et marqu\u00e9e CE, aide les cliniciens \u00e0 diagnostiquer et \u00e0 suivre la progression de maladies telles que la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA), la r\u00e9tinopathie diab\u00e9tique et le glaucome. En transformant les images m\u00e9dicales en informations exploitables, la technologie de RetinAI permet des d\u00e9cisions plus rapides et plus pr\u00e9cises en mati\u00e8re de soins aux patients.<\/p>\n\n\n\n

L\u2019entreprise collabore \u00e9galement avec de grands partenaires pharmaceutiques pour exploiter des donn\u00e9es issues du monde r\u00e9el (Real-World Evidence), acc\u00e9l\u00e9rant ainsi les \u00e9tudes cliniques et soutenant le d\u00e9veloppement de nouveaux traitements. Ces capacit\u00e9s s\u2019alignent \u00e9troitement avec l\u2019objectif d\u2019EssilorLuxottica de cr\u00e9er un \u00e9cosyst\u00e8me de soins visuels enti\u00e8rement int\u00e9gr\u00e9 et fond\u00e9 sur les donn\u00e9es.<\/p>\n\n\n\n

Des diagnostics plus pr\u00e9cis et un meilleur suivi des maladies<\/h4>\n\n\n\n

\u00ab Au cours de l\u2019ann\u00e9e \u00e9coul\u00e9e, nous avons r\u00e9alis\u00e9 plusieurs avanc\u00e9es audacieuses dans le domaine medtech, toutes guid\u00e9es par la volont\u00e9 d\u2019offrir un parcours patient complet et num\u00e9riquement int\u00e9gr\u00e9 \u00bb, a d\u00e9clar\u00e9 Francesco Milleri, CEO d\u2019EssilorLuxottica. \u00ab En tirant parti des analyses bas\u00e9es sur l\u2019IA de RetinAI, nous pouvons transformer les donn\u00e9es cliniques en informations exploitables, permettant des diagnostics plus rapides, plus pr\u00e9cis et un suivi plus efficace des maladies. \u00bb<\/p>\n\n\n\n

Pour Carlos Ciller, PhD, CEO de RetinAI et d\u2019Ikerian, cette acquisition repr\u00e9sente une opportunit\u00e9 d\u00e9terminante : \u00ab Rejoindre EssilorLuxottica marque un moment cl\u00e9 dans notre parcours. Gr\u00e2ce \u00e0 sa port\u00e9e mondiale et \u00e0 son engagement envers l\u2019innovation, nous pouvons d\u00e9sormais concr\u00e9tiser notre vision des soins de sant\u00e9 pilot\u00e9s par les donn\u00e9es \u00e0 une \u00e9chelle et avec un impact in\u00e9dit. \u00bb<\/p>\n\n\n\n

Cette acquisition marque l\u2019aboutissement d\u2019une trajectoire de croissance rapide pour RetinAI<\/a> et sa soci\u00e9t\u00e9 m\u00e8re Ikerian, qui avaient pr\u00e9c\u00e9demment lev\u00e9 USD 6,18 millions lors d\u2019un financement de s\u00e9rie A<\/a> afin d\u2019\u00e9tendre leurs plateformes et capacit\u00e9s bas\u00e9es sur l\u2019intelligence artificielle.<\/p>\n\n\n\n

N\u00e9e \u00e0 Berne comme une spin-off sp\u00e9cialis\u00e9e dans l\u2019imagerie ophtalmique, devenue depuis un partenaire reconnu dans la recherche clinique et pharmaceutique mondiale, l\u2019entreprise illustre la mont\u00e9e en puissance de la Suisse occidentale dans le domaine de la sant\u00e9 num\u00e9rique et de l\u2019intelligence artificielle m\u00e9dicale.<\/p>\n","protected":false},"excerpt":{"rendered":"

L\u2019acquisition de RetinAI par EssilorLuxottica renforce le portefeuille medtech du groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle et les donn\u00e9es, d\u00e9di\u00e9es \u00e0 la gestion des maladies oculaires.<\/p>\n","protected":false},"author":6,"featured_media":35985,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1179,1180,1188,1154,1157],"class_list":["post-35990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr-2","tag-digital-health-fr-2","tag-healthcare-fr-2","tag-investment-fr-2","tag-software-fr-2"],"acf":[],"yoast_head":"\nEssilorLuxottica acquiert RetinAI | GGBa<\/title>\n<meta name=\"description\" content=\"L\u2019acquisition de RetinAI par EssilorLuxottica renforce le groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EssilorLuxottica acquiert RetinAI | GGBa\" \/>\n<meta property=\"og:description\" content=\"L\u2019acquisition de RetinAI par EssilorLuxottica renforce le groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T07:13:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-20T09:23:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"EssilorLuxottica acquiert RetinAI pour acc\u00e9l\u00e9rer l\u2019innovation en sant\u00e9 visuelle pilot\u00e9e par l\u2019IA\",\"datePublished\":\"2025-10-20T07:13:30+00:00\",\"dateModified\":\"2025-10-20T09:23:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\"},\"wordCount\":513,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg\",\"keywords\":[\"Artificial Intelligence\",\"Digital Health\",\"Healthcare\",\"Investment\",\"Software\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\",\"name\":\"EssilorLuxottica acquiert RetinAI | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg\",\"datePublished\":\"2025-10-20T07:13:30+00:00\",\"dateModified\":\"2025-10-20T09:23:40+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"L\u2019acquisition de RetinAI par EssilorLuxottica renforce le groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"L\u2019\u00e9quipe de RetinAI d\u00e9veloppe des logiciels bas\u00e9s sur l\u2019IA pour soutenir le diagnostic pr\u00e9coce et le suivi des maladies oculaires. | \u00a9 RetinAI\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EssilorLuxottica acquiert RetinAI pour acc\u00e9l\u00e9rer l\u2019innovation en sant\u00e9 visuelle pilot\u00e9e par l\u2019IA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EssilorLuxottica acquiert RetinAI | GGBa","description":"L\u2019acquisition de RetinAI par EssilorLuxottica renforce le groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/","og_locale":"fr_FR","og_type":"article","og_title":"EssilorLuxottica acquiert RetinAI | GGBa","og_description":"L\u2019acquisition de RetinAI par EssilorLuxottica renforce le groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle.","og_url":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-20T07:13:30+00:00","article_modified_time":"2025-10-20T09:23:40+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"EssilorLuxottica acquiert RetinAI pour acc\u00e9l\u00e9rer l\u2019innovation en sant\u00e9 visuelle pilot\u00e9e par l\u2019IA","datePublished":"2025-10-20T07:13:30+00:00","dateModified":"2025-10-20T09:23:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/"},"wordCount":513,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg","keywords":["Artificial Intelligence","Digital Health","Healthcare","Investment","Software"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/","url":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/","name":"EssilorLuxottica acquiert RetinAI | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg","datePublished":"2025-10-20T07:13:30+00:00","dateModified":"2025-10-20T09:23:40+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"L\u2019acquisition de RetinAI par EssilorLuxottica renforce le groupe gr\u00e2ce \u00e0 des solutions avanc\u00e9es bas\u00e9es sur l\u2019intelligence artificielle.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/RetinAI-Founders-1180x811-1.jpg","width":2560,"height":1707,"caption":"L\u2019\u00e9quipe de RetinAI d\u00e9veloppe des logiciels bas\u00e9s sur l\u2019IA pour soutenir le diagnostic pr\u00e9coce et le suivi des maladies oculaires. | \u00a9 RetinAI"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/essilorluxottica-acquiert-retinai-pour-accelerer-linnovation-en-sante-visuelle-pilotee-par-lia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"EssilorLuxottica acquiert RetinAI pour acc\u00e9l\u00e9rer l\u2019innovation en sant\u00e9 visuelle pilot\u00e9e par l\u2019IA"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=35990"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35990\/revisions"}],"predecessor-version":[{"id":35992,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/35990\/revisions\/35992"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/35985"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=35990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=35990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=35990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}